We treat the whole range of urological conditions and employ the latest proven techniques using the most up-to-date technology to provide timely and low-risk care for our patients.
We are delighted to have received the Doctify award for Outstanding Patient Experience for the third year in a row
.png "Urology Partners is dedicated to providing all our patients with expert advice, patient choice and the very highest quality of clinical care.")
Practising from London, Surrey, Hampshire and Berkshire, Urology Partners are a group of expert consultant urologists who offer a tailor made approach to your treatment, ensuring you get the best treatment for you and your condition. Our focus on minimally invasive procedures means short hospital stays and rapid return to normal activity. We treat the whole range of Urological Conditions for both men and women.
Professor Richard Hindley talks to Dr Francesca Kum about Rezum treatment for BPH, including the results of clinical trials and the patient experience since starting in 2017.
Andrew Chetwood discusses Urethral Strictures and the Optilume treatment now available
Urology Partners offer the complete portfolio of treatments for minimally invasive surgery to treat Benign Prostatic Hyperplasia (BPH)
Prostate cancer is one of the most common cancers affecting men. The PSA blood test can help detect cancer early when a potentially fatal prostate cancer is still curable, but it can also identify slow-growing cancers that may never cause harm.
This balance — finding significant cancers early while avoiding unnecessary diagnosis and treatment — is why prostate cancer screening remains an important and evolving topic.
In 2026, the UK National Screening Committee recommended targeted screening for men aged 45 to 61 who have a BRCA2 gene variant and a family history of breast, ovarian, pancreatic or prostate cancer. For this group, PSA testing every two years is recommended.
This is not the same as screening all men. Routine PSA screening for the whole male population is still not recommended, because the test can lead to overdiagnosis, unnecessary biopsies, anxiety and treatment side effects.
The PSA test measures prostate-specific antigen in the blood. A raised PSA can be linked to prostate cancer, but it can also be caused by benign prostate enlargement, infection, inflammation or other non-cancerous factors.
That is why PSA testing works best as part of a wider risk assessment, taking into account age, family history, ethnicity, genetic risk and, where appropriate, MRI scanning before biopsy.
Simon Bott, Consultant Urological Surgeon at Urology Partners says “PSA testing for men aged 50-69 years old saves lives from prostate cancer. These men frequently have no symptoms. Screening, invites men to come to have a PSA blood test irrespective of their symptoms, where they live, or if they are seeing a Dr for other reasons. These are the men that benefit most from a PSA blood test.
Currently PSA testing may be done if a man has urinary symptoms (which are unlikely to be related to any cancer in their prostate). Also, if you request a PSA blood test from your GP, the doctor is obliged to perform the test if you are aware of the risks and benefits.
This current UK wide approach of testing men with symptoms or just asking for test from their GP does not target the groups of men who are most likely to benefit. As a result there are currently 10,000 men a year who are over diagnosed with prostate cancer which has a detrimental effect on them due to the side effects of treatment and their mental wellbeing. A national screening programme will remove the pressure on GP’s for PSA testing and allow men to be risk categorised at a younger age which reduces the chance of late diagnosis without the issue of over diagnosis.”
His point highlights the need for a more organised, risk-based approach that helps identify men most likely to benefit from testing while reducing unnecessary harm.
Overdiagnosis can have a real emotional impact. Being told you have cancer can affect mental wellbeing, even when that cancer is unlikely to progress or need immediate treatment.
We support any man aged 45-69 having a PSA test, if their life expectancy exceeds 10-15 years, However, some men are at higher risk of having prostate cancer that matters. Risk is higher with increasing age, a family history of prostate cancer, inherited gene changes such as BRCA2, and Black ethnicity. Men aged 50 and over can discuss PSA testing with their GP, while men at higher risk may wish to have that conversation earlier, particularly from the age of 45.
Symptoms that should prompt medical advice include difficulty passing urine, a weak flow, passing urine more often, blood in the urine or semen, unexplained pelvic or back pain, or new erectile dysfunction. These symptoms are not usually due to prostate cancer, but can be improved with lifestyle changes, medication or sometimes surgery.
We are moving towards a more personalised approach to prostate cancer detection, using risk assessment, MRI-led pathways, genetic testing for selected men and new research to understand who should be screened and when.
For now, the key message is that men should understand their individual risk and seek advice if they are concerned. Screening is no longer simply about whether every man should have a PSA test; it is about identifying who is most likely to benefit.
At Urology Partners, we support informed, evidence-based conversations about prostate cancer risk, PSA testing and modern diagnostic pathways. If you are unsure whether you should be tested, speaking to a specialist can help you make the right decision for you.
We are proud to report on the outstanding contribution from our consultant surgeons at the European Association of Urology (EAU) Annual Congress, held in March 2026—one of the most influential global gatherings in urological innovation, research, and clinical practice.
This year’s congress showcased not only the latest advances in urology but also the expertise and leadership of our team on the international stage. Recognition, live surgical demonstration, and academic presentation underscored our ongoing commitment to improving patient outcomes through evidence‑based, minimally invasive care.
A major highlight of the congress was Mr Neil Barber receiving the Patient Impact Award from Procept Biorobotics. This prestigious award recognises clinicians whose work has made a tangible and lasting difference to patients’ lives.
Neil’s dedication to advancing surgical techniques, specifically with Aquablation therapy, improving patient pathways, and championing outcomes that matter most to patients has been instrumental in shaping modern benign prostatic hyperplasia/obstruction (BPH/BPO) care. This award is a testament not only to his clinical excellence but also to his unwavering focus on patient‑centred innovation.
The recognition by Procept Biorobotics places Neil among a select group of clinicians whose work is influencing the future direction of therapeutic care worldwide.
Further demonstrating the expertise within our team, Mr Amr Emara was invited to perform a live GreenLight™ laser prostate surgery during the congress, broadcast directly from Guy’s Hospital to an international audience of urologists.
Live surgery sessions are among the most technically demanding elements of the EAU programme, requiring exceptional surgical precision, confidence, and the ability to articulate decision‑making in real time. Amr’s live demonstration highlighted the benefits of GreenLight laser technology, including its minimally invasive approach, reduced bleeding risk, and rapid patient recovery.
 |
 |
 |
The session provided valuable insight for delegates seeking to integrate or refine laser therapies within their own clinical practice and reinforced our centre’s role as a leader in advanced endoscopic prostate surgery.
Completing a strong showing from our consultants, Mr Richard Hindley delivered an invited presentation titled:
“A Decade of Evidence and Clinical Experience: Where Do We Advance With Minimally Invasive Therapy for BPO?”
Drawing on twenty years of accumulated data and real‑world outcomes, Richard explored how minimally invasive treatments have evolved, where they have succeeded, and the challenges that remain. His talk addressed the balance between innovation, durability of results, and patient selection—key considerations as new technologies continue to emerge.
The presentation sparked thoughtful discussion among delegates and emphasised the importance of robust clinical evidence when adopting new therapies into routine practice.
The involvement of our consultants at EAU 2026 reflects the breadth of expertise within our department—from award‑winning patient impact and live surgical teaching to authoritative academic leadership. Most importantly, it reinforces our shared mission: to translate innovation and evidence into better care for patients.
We congratulate Neil Barber, Amr Emara, and Richard Hindley on their exceptional contributions and thank them for representing our organisation with such distinction on the global stage.
